The research, published Nov. 25 in Neuroimmunology Reports, found a combination of guanfacine and N-acetylcysteine successfully relieved brain fog in eight out of 12 long COVID-19 patients participating in the study.
Larger, placebo-controlled clinical trials are needed to definitively assess the drugs’ benefits, researchers said. Still, these medications — which are safe, affordable and widely available — may be worth prescribing to long COVID-19 patients with brain fog in the absence of other treatment options.
“There’s a paucity of treatment out there for long COVID brain fog, so when I kept seeing the benefits of this treatment in patients, I felt a sense of urgency to disseminate this information,” study author Arman Fesharaki-Zadeh, MD, PhD, assistant professor of psychiatry and of neurology at Yale, said in a Dec. 13 news release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.